Your browser doesn't support javascript.
loading
Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
Zelin, Enrico; Mazzoletti, Vanessa; Cavallo, Francesco; Nardello, Carlotta; Corio, Andrea; Toffoli, Ludovica; Tagliaferri, Luca; Conforti, Claudio; Di Meo, Nicola; Zalaudek, Iris.
Afiliación
  • Zelin E; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
  • Mazzoletti V; Department of Health Science, University of Eastern Piedmont, Novara, Italy.
  • Cavallo F; Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Nardello C; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
  • Corio A; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
  • Toffoli L; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
  • Tagliaferri L; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.
  • Conforti C; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
  • Di Meo N; Dermatological Research Hospital, IDI IRCCS, Rome, Italy.
  • Zalaudek I; Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Australas J Dermatol ; 65(2): 103-113, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37927116
Locally advanced (laBSCs) and metastatic basosquamous carcinomas (mBSCs) represent a therapeutic challenge. By definition, these forms are not amenable to surgery or radiotherapy, but according to literature reports, sonic hedgehog pathway inhibitors (HHIs), anti-programmed death 1 receptor antibodies (anti-PD-1), and other treatment approaches involving chemotherapy, surgery, and radiotherapy have been used. This work features 5 real-life cases of advanced BSCs, treated at the Dermato-Oncology Unit of Trieste (Maggiore Hospital, University of Trieste). In addition, a review of the current treatment options reported in the literature for laBSC and mBSC is provided, collecting a total of 17 patients. According to these preliminary data, HHIs such as sonidegib and vismodegib could represent a safe and effective first line of treatment, while the anti-PD-1 cemiplimab may be useful as a second-line option. Chemotherapy and combined approaches involving surgery and radiotherapy have been also reported to be suitable in some patients.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Carcinoma Basocelular / Carcinoma Basoescamoso / Antineoplásicos Límite: Humans Idioma: En Revista: Australas J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Carcinoma Basocelular / Carcinoma Basoescamoso / Antineoplásicos Límite: Humans Idioma: En Revista: Australas J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Italia